Compare Citius Pharmaceuticals Inc (CTXR) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Medpace Holdings Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Medpace Holdings Inc trades at $533.33 (market cap $15.31B). The key difference: Medpace Holdings Inc is far larger — about 1045.8× Citius Pharmaceuticals Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | MEDP | |
|---|---|---|
Market Cap | $14.64M | $15.31B |
Sector | Health | Technology |
52-Week High | $1.82 | $620.59 |
52-Week Low | $0.53 | $308.88 |
Enterprise Value | $10.86M | $14.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
MEDP trades at $530.19, down 1.49% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected on July 22, 2026. Fundamentals show robust profitability with a 17.19% net income margin and 77.25% ROE, though valuation ratios like P/E of 33.74 are elevated. Recent news highlights volatility and a class action lawsuit filed in June 2026.
Outlook is mixed; earnings momentum and high profitability support upside, but high valuation and legal overhang pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term gains. Investors should weigh strong operational performance against valuation concerns and litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
